BIOXYDYN: Magnetic Resonance Imaging Biomarkers

Impact: Health impacts, Economic impacts

Narrative

Magnetic resonance imaging (MRI) provides measurements for quantitative, non-invasive, diagnostic, repeatable monitoring of disease. MRI biomarkers research at the University of Manchester (UoM) spans cancer, lung disease, neurology and more. Our research has produced methods that are widely used by the pharmaceutical industry for drug development decision-making (including ≥ seven AstraZeneca development molecules, plus other pharma), leading to economic benefit, and for healthcare impact (e.g., influencing diagnostic MRI tools introduced by Philips and creating new tools via spin-outs). The methods have been delivered in part via an award-winning UoM spin-out SME, Bioxydyn (incorporated 2009; 2012 turnover £630K; employing 12 staff).
Impact date2014
Category of impactHealth impacts, Economic impacts
Impact levelBenefit

Documents & Links

Related content